Catherine graduated from King’s College, University of Cambridge in 2000 and earned her PhD from Corpus Christi College, University of Cambridge. In 2003, she joined Abcam where she assisted with a successful IPO on AIM and was a member of the senior management team. She returned to academic research in 2015 as a Daphne Jackson fellow at the Wellcome Sanger Institute. She co-founded Qkine in 2016 to address challenges in the growth factor and complex protein supply chain and to support innovations in stem cell science and regenerative medicine; areas she believes underpin future advances in human health and wellbeing.
Clair ParsonsHead of Finance and Operations
Clair has over 30 years of experience in finance. Prior to working at Qkine, Clair was the Head of Financial Planning and Analysis at Abcam. During the 15 years that she worked at Abcam, Clair helped to scale the finance department from just one member of staff to a team of more than 50 people. During her career she has supported three start-up companies through their early growth phases, including Syndicate Room. Clair joined Qkine in 2020 to help build scalable systems and processes within Finance and Operations to enable the company to move into the next phase of its growth.
Alison RawlinsonHead of Marketing
Alison is a trained microbiologist with an MPhil in Biochemistry from the University of Cambridge. She has more than 10 years of research experience in both academic and pharmaceutical environments. Alison gained her CIM certificate in professional marketing and has worked for multiple global scientific manufacturers in sales and marketing positions. In 2019, Alison grew an established academic account by 10% and was awarded the field sales account manager of the year for Western Europe at Merck. Alison joined Qkine in 2022 to help ensure that the company exceeds customers’ needs and expectations in the growth factor market.
Dr Andy DayHead of Product Development and Manufacture
Andy is a molecular and cell biologist with over 20 years of experience in product development and manufacturing. He graduated from the University of Sheffield in 1995 before joining PIC, based in the Department of Pathology at the University of Cambridge. Whilst at PIC, Andy studied part-time for a Ph.D. investigating genes involved in porcine male fertility. He worked at Abcam from 2007 – 2018, before moving to the Wellcome Sanger Institute as a Senior Scientific Manager within the Cellular Generation and Phenotyping team. He joined Qkine in 2022 to expand both Manufacturing and Product Development capabilities within the company to ensure the continuous supply of high-quality reagents to customers whilst meeting future demands.
Jim graduated from Christ’s College, Cambridge in 1986 and then joined Analysys Limited where he headed up their IT, software and web development initiatives. In 2000 he moved to Abcam as a Technical Director. He took over the operational management of the UK office as Managing Director in 2004, working on Abcam’s growth plans and efficiency improvement programmes. In 2009, Jim became Chief Operating Officer, with responsibility for overseeing the operational strategy of the Group. Jim left Abcam at the end of 2016 and is currently a NED for Cambridge Nutraceuticals Limited and the AIM listed Quartix Plc.
Dr Marko HyvönenCSO & Founder
Marko is a structural biochemist with over 20 years of experience in producing complex proteins for structural analysis. He studied biochemistry at the University of Helsinki and did his PhD at the European Molecular Biology Laboratory in Heidelberg. He joined the Department of Biochemistry in Cambridge in 1998. Since 2001 he has been leading a research group, studying the structure and function of TGF-beta family growth factors, with a particular focus on activins. He runs a core facility providing high-quality growth factors and other protein-based tools for the stem cell research consortium at the University of Cambridge.
Dr Cassie DohertyNon-executive Director
Cassie is Investment Director with Parkwalk Advisors. She has worked in life sciences investment for over 10 years. She sits on the Boards of several portfolio companies, taking an active role in supporting their strategic, technical and commercial plans. Companies Cassie has worked with have cumulatively raised over £50 million of investment and she has been involved in M&A and licensing deals. Prior to working in life sciences investment, Cassie led drug development programmes based on her academic research into Phase II clinical studies. She holds a PhD in Biochemistry and Molecular Biology from the University of Leeds.
Dr Robert ScoffinNon-executive Director
Rob graduated from Pembroke College, Oxford in 1987 with a degree in chemistry, and then went on to complete his D.Phil. He then joined Oxford Molecular Limited where he worked his way up from junior software developer to head of external collaborations, working with a group of large Pharma clients on innovative software solutions to drug discovery challenges. In 1998, Rob joined CambridgeSoft Inc. As VP of European Operations, Rob was responsible for the growth of a $20m business. Rob left CambridgeSoft in 2010 to become CEO of Cresset, a growing Cambridge-based computational chemistry software and services company.
Dr Christine MartinNon-executive Director
An Investment manager in the Life Sciences team at Cambridge Enterprise, Christine has a focus on drug discovery with a broad portfolio of technologies, including University of Cambridge spin-outs Carrick, STORM, Z-factor, PhoreMost, Qkine and PolyProX. Christine has extensive experience in Life Sciences Tech Transfer and supporting early stage companies at Board level. She was a Department Director and Project Leader at Biotica, a biotechnology spin-out from the University of Cambridge. Christine has an MA and DPhil from the University of Oxford. She is the author of over 20 peer reviewed journal articles and over 20 patents.